← Back to Search

Vaccine

Vaccine Immune Response Study in Healthy Subjects

N/A
Waitlist Available
Led By Taia T Wang, MD PhD
Research Sponsored by Rockefeller University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or Female 18-80 years of age
Willing to receive a single dose of an FDA-approved vaccine (either the influenza virus, pneumococcal or meningococcal vaccine)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one day
Awards & highlights

Study Summary

This trial will help researchers understand why some people have a better immune response to vaccination than others, in order to develop more effective vaccines.

Who is the study for?
This trial is for healthy adults aged 18-80 who have had or not had dengue, zika, or chikungunya virus. Participants must be willing to receive an FDA-approved vaccine (flu, pneumococcal, or meningococcal) and commit to the study for 12 weeks. Exclusions include pregnancy, lactation, immune system issues like HIV/hepatitis B/C, recent receipt of the same vaccines, certain medical conditions including immunodeficiency/autoimmune diseases or substance abuse.Check my eligibility
What is being tested?
The study investigates how different vaccines affect antibody (IgG Fc glycan) composition in human immunity among healthy volunteers. The goal is to understand what makes a vaccine response effective and could lead to improved adjuvants that enhance this response.See study design
What are the potential side effects?
While specific side effects are not listed for this trial as it involves approved vaccines with known profiles; generally flu shots can cause soreness at injection site, feverish feelings; pneumococcal may result in redness/swelling at injection site; meningococcal might cause mild fever and muscle pain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old.
Select...
I am willing to get a flu, pneumonia, or meningitis vaccine.
Select...
I am healthy with no significant medical issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one day
This trial's timeline: 3 weeks for screening, Varies for treatment, and one day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The degree of galactosylation, fucosylation and sialylation

Trial Design

3Treatment groups
Active Control
Group I: Biologic/Vaccine, Age 18-64 cohortActive Control1 Intervention
Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
Group II: Biologic/Vaccine, Age 65-80 cohortActive Control1 Intervention
Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
Group III: Vaccine, healthy adultsActive Control1 Intervention
Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Find a Location

Who is running the clinical trial?

Rockefeller UniversityLead Sponsor
158 Previous Clinical Trials
16,217 Total Patients Enrolled
Taia T Wang, MD PhDPrincipal InvestigatorRockefeller Univesrity

Media Library

Flu Vaccine (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT01967238 — N/A
Healthy Subjects Research Study Groups: Biologic/Vaccine, Age 18-64 cohort, Biologic/Vaccine, Age 65-80 cohort, Vaccine, healthy adults
Healthy Subjects Clinical Trial 2023: Flu Vaccine Highlights & Side Effects. Trial Name: NCT01967238 — N/A
Flu Vaccine (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01967238 — N/A
Healthy Subjects Patient Testimony for trial: Trial Name: NCT01967238 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the door open for participation in this clinical experiment?

"According to the clinicaltrials.gov database, this trial is no longer recruiting participants; it was first posted on March 1st 2013 and last updated on May 31th 2022. Nonetheless, 859 other medical studies are still looking for volunteers at present."

Answered by AI

What is the current enrollment size of this clinical experiment?

"Unfortunately, this trial has closed to new recruits. It was posted on March 1st 2013 and last updated on May 31st 2022. Currently, there are 839 active trials recruiting healthy subjects (HS) along with 20 studies enrolling patients of 65-80 age cohort for biologics/vaccines."

Answered by AI

Are there any previous investigations regarding Biologic/Vaccine treatments concerning people aged 65 to 80?

"At this moment, Biologic/Vaccine studies for the 65-80 age cohort have 20 active trials in progress with 8 at Phase 3. Out of these 584 trial locations across North America, a majority are situated around Newmarket, Ontario."

Answered by AI

Who would be a suitable candidate for participation in this research?

"Eligibility for this trial necessitates healthy subjects within the age range of 18-80. 140 patients are planned to be recruited in total."

Answered by AI

Does the protocol for this clinical trial permit individuals who are under seventy-five to participate?

"The age range for individuals that are allowed to enrol in this trial is 18-80 years old."

Answered by AI

Who else is applying?

What state do they live in?
New York
What site did they apply to?
The Rockefeller University
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I'm a strong believer in vaccines and what they can contribute to public health. Also, I live a couple of blocks away :).
PatientReceived no prior treatments
Recent research and studies
Proceedings of the National Academy of SciencesJournal
Increasing the Breadth and Potency of Response to the Seasonal Influenza Virus Vaccine by Immune Complex Immunization
Maamary, Jad, Taia T. Wang, Gene S. Tan, Peter Palese, and Jeffrey V. Ravetch. 2017. “Increasing the Breadth and Potency of Response to the Seasonal Influenza Virus Vaccine by Immune Complex Immunization”. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1707950114.
clinicaltrials.govStudy
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
2013. "An Open Label Study of IgG Fc Glycan Composition in Human Immunity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01967238.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top